CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announced a proposed private offering of $350 million aggregate principal amount of convertible senior notes due 2031, with an initial purchaser option of up to $52.5 million. Interest will accrue semiannually beginning September 1, 2026, and notes mature March 1, 2031. Upon conversion, the company will deliver common shares. The company intends to use net proceeds for general corporate purposes. Terms including interest rate and conversion rate will be set at pricing; the notes and shares will not be registered under the Securities Act.

Positive

• $350 million primary financing via convertible notes
• Upsize option of $52.5 million increases potential proceeds
• Proceeds designated for general corporate purposes
• Long-dated maturity provides 2026–2031 financing runway

Negative

• Conversion will issue common shares, causing shareholder dilution
• Notes are senior unsecured, offering no collateral protection
• Interest accrues semiannually starting Sept 1, 2026, adding cash cost

News Market Reaction – CRSP

-10.17% 3.8x vol

93 alerts

-10.17% Session close to close

-9.8% Trough in 32 hr 58 min

$5.64B Market Cap

3.8x Rel. Volume

In the Mar 10 session, CRSP declined 10.17%, reflecting a significant negative market reaction. Argus tracked a trough of -9.8% from its starting point during tracking. Our momentum scanner triggered 93 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.8x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.2% in the session following this news. A negative reaction despite the company...

Analysis

The stock dropped -10.2% in the session following this news. A negative reaction despite the company’s recent pattern of positive responses to news would fit concerns that a convertible note financing could introduce dilution and create an overhang from future share issuance upon conversion. Past announcements generally tracked with constructive moves, so a sharp decline could also reflect positioning and profit-taking after prior strength rather than a shift in underlying fundamentals.

Key Figures

Base offering size: $350 million Overallotment option: $52.5 million Maturity year: 2031 +4 more

7 metrics

Base offering size $350 million Convertible senior notes due 2031

Overallotment option $52.5 million Additional convertible notes for initial purchasers

Maturity year 2031 Convertible senior notes maturity date

Settlement window 13 days Period for exercising additional notes option

Par value per share CHF 0.03 Nominal value of common shares on conversion

First interest payment September 1, 2026 Semiannual interest on convertible notes

Interest payment dates March 1 and September 1 Semiannual schedule for note interest

Historical Context

5 past events · Latest: Feb 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 12	Earnings and update	Positive	+8.5%	Q4 and 2025 results with CASGEVY revenue and broad pipeline progress.
Jan 12	Strategic outlook	Positive	+2.7%	Outlined 2026 priorities, milestones, and CASGEVY commercialization metrics.
Jan 05	Conference presentation	Positive	+2.6%	Announcement of presentation at J.P. Morgan Healthcare Conference.
Dec 22	Clinical update	Positive	+3.7%	Zugo‑cel efficacy and safety data across autoimmune and lymphoma settings.
Nov 10	Earnings and update	Positive	-1.0%	Q3 2025 financials, CASGEVY metrics, and multiple pipeline readouts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent CRSP news, especially earnings and strategic updates, has more often been followed by positive price reactions, with only one mild divergence on an earnings report.

Recent Company History

Over the past few months, CRISPR Therapeutics has reported growing CASGEVY revenue, rising from Q3 updates to Q4 and full-year 2025 results, while maintaining cash balances around $1.9–2.0B. Business updates on zugo‑cel and in vivo programs, plus strategic 2026 milestones, generally coincided with positive single‑digit price moves. Against this backdrop, the newly announced convertible notes offering follows a period of strength and active clinical and commercial execution highlighted in news on Nov 10, 2025 through Feb 12, 2026.

Key Terms

convertible senior notes, qualified institutional buyers, rule 144a, senior, unsecured obligations, +3 more

7 terms

convertible senior notes financial

"its convertible senior notes due 2031 (the “notes”) in a private offering"

Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.

qualified institutional buyers financial

"in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers"

Qualified institutional buyers are large organizations, like big investment firms or banks, that are allowed to buy certain types of investment opportunities not available to everyday investors. Their size and experience matter because it ensures they understand and can handle complex financial deals, making markets more efficient and secure.

rule 144a regulatory

"pursuant to Rule 144A under the Securities Act of 1933, as amended"

Rule 144A is a regulation that makes it easier for companies to sell private bonds to large investors without going through all the usual rules that apply to public sales. It matters because it helps companies raise money more quickly and privately, often attracting big investors looking for special deals.

senior, unsecured obligations financial

"The notes will be senior, unsecured obligations of the Company and will accrue interest"

Senior, unsecured obligations are loans or bonds that a company promises to repay before lower-ranked (subordinated) creditors but without specific collateral backing them. They matter to investors because they combine relatively higher priority in a company’s payment order with greater risk than secured debt, so they typically offer higher yields and influence how much money investors could recover if the company runs into financial trouble.

in arrears financial

"will accrue interest payable semiannually in arrears on March 1 and September 1 of each year"

In arrears means a payment that was due has not been made on time, or that payments are scheduled to be made after the period they cover (for example, paying interest at the end of a month rather than at the start). For investors, arrears matter because they indicate possible cash-flow strain or higher credit risk and change when income or expenses are recognized—like a landlord not getting rent when expected, which can signal trouble or alter available cash.

general corporate purposes financial

"The Company intends to use the net proceeds from the offering for general corporate purposes."

"General corporate purposes" refer to the broad range of activities and expenses a company can use its funds for to support its overall operations and growth. This can include things like paying bills, investing in new projects, or strengthening its financial position. For investors, understanding this term helps clarify how a company plans to use its resources to sustain and expand its business over time.

registered under the securities act regulatory

"have not been, and will not be, registered under the Securities Act or any other securities laws"

Means a company has filed required paperwork with the securities regulator so a stock or other security can be offered or sold to the public; the filing makes key financial and business information available to investors. Like handing out a detailed product label before sale, registration gives buyers reliable facts, legal protections and usually easier resale of the security, which helps investors assess risk and compare opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5 million aggregate principal amount of the notes.

The notes will be senior, unsecured obligations of the Company and will accrue interest payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2026. The notes will mature on March 1, 2031, unless earlier converted, redeemed or repurchased. Upon conversion, the Company will deliver common shares, nominal value CHF 0.03 per share (“common shares”). The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

The Company intends to use the net proceeds from the offering for general corporate purposes.

The offer and sale of the notes and the common shares deliverable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or the common shares deliverable upon conversion of the notes, nor will there be any sale of the notes or such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About CRISPR Therapeutics

Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY^® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

CRISPR THERAPEUTICS^® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY^® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the proposed terms of the notes, the size of the offering and the expected use of the proceeds from the sale of the notes. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, risks related to or associated with whether the Company will consummate the offering on the expected terms, or at all, which could differ or change based upon market conditions or other reasons, and the other risks and uncertainties discussed under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact:
+1-617-307-7503
ir@crisprtx.com

Media Contact:
+1-617-315-4493
media@crisprtx.com

FAQ

What amount of convertible senior notes did CRSP announce on March 10, 2026?

CRISPR announced a proposed private offering of $350 million in convertible senior notes, with an initial purchaser option up to $52.5 million. According to the company, final interest and conversion terms will be set at pricing.

When do the CRSP convertible notes mature and when does interest begin?

The notes mature on March 1, 2031 and interest begins September 1, 2026, paid semiannually. According to the company, interest payments occur March 1 and September 1 each year thereafter.

How will conversion of CRSP's notes affect existing shareholders?

Upon conversion, the company will deliver common shares, which may dilute existing ownership. According to the company, conversion mechanics and rates will be determined at the offering pricing.

Who can purchase the CRSP convertible notes in this offering?

The offering is a private sale to persons reasonably believed to be qualified institutional buyers (QIBs) under Rule 144A. According to the company, the notes and deliverable shares are not registered under the Securities Act.

What does CRSP intend to use the proceeds from the convertible notes for?

CRISPR intends to use net proceeds for general corporate purposes, providing flexibility for operations and financing. According to the company, no specific project allocations were disclosed in the announcement.